Cutaneous reactions to alimentary tract medications: Results of a seven-year surveillance program and review of the literature

Dermatology

Volumn 193, Issue 1, 1996, Pages 11-16

  Naldi, L ^a   Ferri, C ^a   De sanctis, S ^a   Camelli, T ^b   Rebora, A ^b   Tognoni, G ^b   Peserico, A ^b,m   Grimakli filioli, F ^c   Villano, P A ^c   Moscaricllo, C ^c   Guerrera, V ^c   Fiorio, M ^c   Pisani, M ^c   Locati, F ^d   Falgheri, G ^d   Di landro, A ^d   Barcella, A ^d   Reseghetti, A ^d   Imberti, G ^d   De bitonto, A ^d   Mariani, A ^d   Pansera, B ^d   Puiatti, P ^e   Fassino, M ^e   Tomidei, M ^e   Doveil, G ^e   Annunziata, M ^e   Zina, A M ^e   Forte, M ^e   Filotico, R ^f   Foti, C ^f   Angelini, G ^f   Vena, G A ^f   Arcangeli, F ^g   Brighi, L ^g   Fcletti, S ^g   Leardini, M ^g   Polverelli, M ^g   Laudi, G ^g   Tosti, A ^h   Misciali, C ^h   D'antuono A ^h   Zucchelli, V ^h   Varotti, C ^h   Baiato, N ⁱ   Derosa, S ⁱ   Bordone, F ⁱ   Patruno, C ⁱ   Santoianni, P ⁱ   Virgili, A R ^j   Strumia, R ^j   Colombo, V ^j   Negrini, A ^j   Califano, A ^j   Marinaro, P ^g   Riva, M I ^g   Gennari, L ^g   Galbiati, G ^g   Pasolini, G ^g   Manganoni, A ^g   Leali, C ^g   Carlino, A ^g   Schena, D ^k   Barba, A ^k   Veraldi, S ^l   Rizzitelli, G ^l   Caputo, R ^l   Veller fornasa, C ^m   Poletto, S ^m   Cusano, F ^g   Galiuccio, A G ^g   Capozzi, M ^g   Burroni, A ⁿ   Nigro, A ⁿ   Farris, A ⁿ   Fanti, A ^g   Lombardi, P F ^g   Dilorio, S ^g   Becchilega, R ^g   Perno, P ^o   Lisi, P ^o   Pestarino, A ^p   Arinomele, A ^p   Massone, L ^p   laniuntuono, M ^q   Lumino, M ^q   Giovanni, S ^q   Robert, E ^r   Rongioletti, F ^r   Betti, R ^s   Crosti, C ^s   Diprima, T ^t   Sapuppo, A ^t   Locatelli, A ^g   Saggiorato, F ^g   Feniz, G ^g   Altobella, L ^g   Moretti, S ^u   Barcolla, L ^v   Palleschi, G M ^u   Scardigli, F ^g   Kokelj, F ^w   Cimitan, A ^x   Taddcucci, P ^y   Cannata, G ^z   Ingordo, V ^aa   more..

^a UNIVERSITY OF MILAN   (Italy)

^b Der matological Service of th locai generai hospital   (Italy)

^c Napoli I Clinica Universitaria   (Italy)

^d Bergamo Clinica Universitaria   (Italy)

^e Torino Clinica Universitaria   (Italy)

^f UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^g Bologna Clinica Universitaria ^*  (Italy)

^h Napoli II Clinica Universitaria   (Italy)

ⁱ Ferrara Clinica Universitaria   (Italy)

^j UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^k Genova Ospedale San Martino   (Italy)

^l Clinica Dermatologica Perugia   (Italy)

^m UNIVERSITY HOSPITAL OF PADOVA   (Italy)

ⁿ UNIVERSITY OF GENOA   (Italy)

^o Firenze II Clinica Universitaria   (Italy)

^p UO Hematology EO Galliera   (Italy)

^q Milano Clinica Universitaria ^*  (Italy)

^r UNIVERSITY OF GENOA   (Italy)

^s SAN PAOLO HOSPITAL   (Italy)

^t Catania Clinica Universitaria   (Italy)

^u Firenze II Clinica Universitaria   (Italy)

^v Milano II Clinica Universitaria   (Italy)

^w Trieste Clinica Universitaria   (Italy)

^x UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^y Siena Clinica Universitaria   (Italy)

^z Ospedale Civile di Albenga   (Italy)

^aa Ospedale Marina Militare Taranto   (Italy)

more..

Author keywords

Adverse drug reactions; Alimentary tract medications; Post marketing surveillance; Skin

Indexed keywords

ANTIEMETIC AGENT; ANTIULCER AGENT; CISAPRIDE; LAXATIVE; MESALAZINE; SPASMOLYTIC AGENT;

ARTICLE; DRUG SAFETY; GASTROINTESTINAL DISEASE; HUMAN; ITALY; LICHENOID ERUPTION; MEDICAL LITERATURE; PRIORITY JOURNAL; RASH; URTICARIA;

DRUG ERUPTIONS; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; HUMANS; INCIDENCE; ITALY; PRODUCT SURVEILLANCE, POSTMARKETING; PROGRAM EVALUATION; RISK FACTORS;

EID: 9344226740     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000246191     Document Type: Article

References (62)

1. Garattini S. Garatlini L: Pharmaceutical prescriptions in four European countries. Lancet 1993;342:1191-1192.
2. Wormsley KG: Safety profile of ranitidine. Drugs 1993;46:976-985.
3. Colin-Jones DG. Langman MJ, et al: Post-marketing surveillance of the safety ofcimeti-dine: 10 year mortality report. Gut 1992:33: 1280-1284.
4. Lipsy RJ. Fennerty B. et al: Clinical review of histamine-2 receptor antagonists. Arch Intern Med 1990:150:745-751.
5. Andersen M. Schou JS: Adverse reactions to H,-receptor antagonists in Denmark before and after transfer of cimetidine and ranitidine to over-the-counter status. Pharmacol Toxicol 1991:69:253-258.
6. Gattuso JM. Kamm MA: Adverse effects of drugs in the management of constipation and diarrhoea. Drug Safety 1994:10:47-65.
7. Gruppo Italiano Studi Epidemiologici in Der-matologia (GISED): Spontaneous monitoring of adverse reactions to drugs by Italian dermatologists: A pilot study. Dermatologica 1991: 182:12-17.
8. Gruppo Italiano Studi Epidemiologici in Der-matologia (GISED): Cutaneous reactions to analgesic-antipyretics and nonsteroidal antiinflammatory drugs. Dermatology 1993:186: 164-169.
9. Karch FE. Lasagna I.: Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther 1977;21:247-254.
10. Venulet J: Some aspects of drug monitoring. Adv Drug React Pois Rev 1985:3:161-175
11. Garcia-Rodriguez LA. Jick H: Risk of gynae-comastia associated with cimetidine. omeprazole, and other antiulcer drugs. Br Med J 1994: 308:503-506.
12. Lazaro M. Compaired JA. et al: Anaphylactic reaction to ranitidine. Allergy 1993:48: 385-387.
13. Powell JA. Maycock EJ: Anaphylactoid reaction to ranitidine in an obstetric patient. An-aesth IntensCarc 1993:21:702-703.
14. Barry JE. Madan R. et al: Anaphylactoid reaction to ranitidine in an obstetric patient. Anaesthesia 1992:47:360-361.
15. Greer IA, Fellows K: Anaphylactoid reaction to ranitidine in labour. Br J Clin Pract 1990: 44:78.
16. Juste S. Blanco J. et al: Allergic dermatitis due to oral ranitidine. Contact Dermatitis 1992:27: 339-340.
17. Bossi A. Romeo G. et al: Side-effects, structure. and H,-receptor antagonists. Lancet 1992: 339:1366.
18. Karras DJ: Severe low back pain secondary to acute interstitial nephritis following administration of ranitidine. Am J Emerg Med 1994: 12:67-68.
19. Devuyst O. Lefebvre C. et al: Acute cholestatic hepatitis with rash and hypereosinophilia associated with ranitidine treatment. Acta Clin Bel 1993:48:109-114.
20. Raffle EJ: Cimetidine and psoriasis (letter). Lancet 1978:Vol ii: 1314.
21. McCallum DI. Grant PW: Cimetidine and psoriasis. Lancet 1978:Vol ii: 1314-1315.
22. Rai GS. Webster SGP: Cimetidine and psoriasis (letter). Lancet 1979:Vol I:50.
23. Andreo JA. Vivancos F. et al: Leukocytoclastic vasculitis and famotidine. Med Clin Bare 1990:95:234-235.
24. Giacosa A. Farris A. Chcli R: Cimetidine and psoriasis (letter). Lancet 1978:Vol ii: 1211-1212.
25. Nielsen HJ. Nielsen H. Georgson J: Ranitidine for improvement of treatment-resistant psoriasis. Arch Dermatol 1991:127:270.
26. Castol A. Bidault I. Dahan R. Efthymiou ML: Bilan des effets inattendus et toxiques de l'omeprazole rapportes aux centres régionaux de pharmacovigilance, au cours des 22 premiers mois de commercialisation. Therapie 1993:48:469-474.
27. Bowlby HA. Dickens GR: Angioedema and urticaria associated with omeprazole confirmed by drug rechallcnge. Pharmacotherapy 1994:14:119-122.
28. Sivakumar K. Dalakas MC: Autoimmune syndrome induced by omeprazole. Lancet 1994: 344:619-620.
29. Chosidow O. et al: Pemphigoide bulleuse secondairement corticorésistantc: rôle inhibiteur de l'omeprazole sur le métabolisme des corticoïdes? Ann Dermatol Vénéréol 1991:118:45.
30. Cox NH: Acute disseminated epidermal necrosis due to omeprazole. Lancet 1992:340:857.
31. Stcnier C. Fiasse R. Bourlond J. Horsmans Y. Bourlond A: Bullous skin reaction induced by omeprazole. Br J Dermatol 1995:133: 343-344.
32. Yasue T, Nitta Y: Domperidone induced systemic lupus-like syndrome. J Dermatol 1986: 13:293.
33. Bruinsma W: A Guide to Drug Eruptions: The File of Side Effects in Dermatology. Amsterdam. Free University of Amsterdam, 1995.
34. Zürcher K. Krebs A: Cutaneous Drug Reactions: An Integral Synopsis of Today's Systemic Drugs. Basel. Karger. 1992.
35. Fisher MMcD: Severe histamine mediated reactions to intravenous drugs used in anaesthesia. Anaesth Intens Care 1975:3:180-197.
36. Gordon FM. Sltupak A. Doweck I. Spitzer O: Allergic contact dermatitis caused by transder-mal hyoscine. Br Med J 1989:298:1220-1221.
37. Zanolli MD. McAlvany J. et al: Phcnolphlha-lein-induced fixed drug eruption: A cutaneous complications of laxative use in a child. Pediatrics 1993:91:1199-1201.
38. Bouvier P. Buffièrc I. et al: Immediate allergic raction after ingestion of a dietary bar containing psyllium. Presse Méd 1993:22:173.
39. Sussman GL. Dorian W: Psyllium anaphylaxis. Allergy Proc 1990:11:241-242.
40. Lantner RR. Espiritu BR. et al: Anaphylaxis following ingestion of a psyllium containing cereal. JAMA 1990:264:2534-2536.
41. Harland CC. Mortimer PS: Laxative-induced contact dermatitis. Contact Dermatitis 1992: 27:268- 269.
42. Meyers AM. Feldman C. et al: Chronic laxative abusers with pseudo-idiopathic oedema and autonomous pseudo Banter's syndrome: A spectrum of metabolic madness, or new lights on an old disease? S Air Med J 1990:78: 631-636.
43. Roujeau JC. Kelly JP. Naldi L. et al: Drug etiology of Stevens-Johnson syndrome and toxic epidermal necrolysis: First results from an international case-control study. N Engl J Med 1995:333:1600-1607.
44. Farr M. Scott DGI. Bacon PA: Side effect profile of 200 patients with inflammatory arthi-tidcs treated with sulphasalazine. Drugs 1986: 32(suppl 1):49-53.
45. Amos RS. Pullar T. Bax DE. et al: Sul-phasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years. Br Med J 1986;293:420-423.
46. Marce S, Schaeverbeke T. et al: Generalized acute exanthematous pustulosis after ingestion of sulfasalazine. Presse Méd 1993:22:271.
47. Marcus RW: Sulfasalazine induced taste disturbances. J Rheumatol 1991;18:634-635.
48. Walker EM, Carty JE: Sulphasalazine-induced systemic lupus erythematosus in a patient with erosive arthritis. Br J Rheumatol 1994:33: 175-176.
49. De Keyser F, Mielants H, et al: Changes in antinuclear serology in patients with spondyl-arthropathy under sulphasalazine treatment. Br J Rheumatol 1993:32:521.
50. Dawes PT, Shadfort MF: Sulfasalazine induced oral lichen planus. Br Med J 1984:288: 194.
51. Bargon J, Rust M, et al: Salazosulfapyridine induced eosinophilic pneumonia with pulmonary and cutaneous epithelioid cell granulomatosis in Sjogren syndrome. Pncumologie 1990: 44:744-750.
52. Gruppo Italiano Studi Epidemiologici in Dermatologia (GISED): Epidemiological evidence of the association between lichen planus and two immune-related diseases: Alopecia areata and ulcerative colitis. Arch Dermatol 1991;127:688-691.
53. Brooks H. Taylor HG. et al: The three-week sulphasalazine syndrome. Clin Rheumatol 1992;11:566-568.
54. Guillaume JC. Roujcau JC, Rcvuz J, Penso D. Touraine R: The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyelf syndrome). Arch Dermatol 1987; 123:1166-1170.
55. Bliddal H, Slangerup M: Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy. Clin Rheumatol 1991;10:178-180.
56. Gupta AK, Ellis CN, et al: Sulfasalazine improves psoriasis: A double-blind analysis. Arch Dermatol 1990;126:487-493.
57. Brimblccombe R: Mesalazine: A global safety evaluation. Scand J Gastroenterol 1990; 172: 66.
58. Fardy JM, Lloyd DA. Reynolds RP: Adverse effects with oral 5-aminosalicylic acid. J Clin Gastroenterol 1988; 10:635-637.
59. Le Gros V, Saveuse H, Lesur G: Lung and skin hypersensitivity to 5-aminosalicylic acid. Br MedJ 1991:302:970.
60. Haulekeete ML, Bourgeois N, et al: Hypersensitivity with hepatoloxicity to mesalazine after hypersensitivity to sulfasalazine. Gastroenterology 1992:103:1925-1927.
61. Waanders MD. Thompson J: Kawasaki-like syndrome after treatment with mesalazine. Am J Gastroenterol 1991:86:219-221.
62. Alstcad EM. Wilson AG, et al: Lichen planus and mesalazine. J Clin Gastroenterol 1991; 13: 335-337